Navigation Links
Cytopia Lodges IND for JAK2 Inhibitor CYT387
Date:6/22/2009

in diseases driven by disregulated JAK2 signalling, including some cancers and various inflammatory conditions. Cytopia is

exploring the utility of CYT387 in these conditions.

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the development of new drugs to treat cancer and other diseases. Cytopia conducts its drug development through subsidiaries based in Australia

and USA and specializes in developing new small molecule compounds with an improved therapeutic profile for the treatment of cancer.

The lead program for the company is CYT997, a vascular disrupting agent (VDA) for the treatment of various cancers, currently being trialed in Phase II clinical studies. This compound is delivered orally as well as intravenously. Cytopia also has built on its range of JAK and other kinase inhibitors with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders and cancer, expected to enter Phase I clinical studies in 2009.


'/>"/>
SOURCE Cytopia Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Cytopia To Present Data on FMS Program With Anticancer Potential
2. Cytopia Commences Phase II Cancer Drug Study
3. Potent metastasis inhibitor identified
4. Small molecule inhibitor shows promise in trastuzumab-resistant metastatic breast cancer
5. Cylene to Announce New Data on Its First-in-Class Oral CK2 Inhibitor Against Cancer at BIO Conference
6. For the Treatment of Rheumatoid Arthritis, Market Share for TNF-alpha Inhibitors Will Decrease Through 2018
7. Video: Novartis Receives Approval From FDA to Market Prevacid(R) 24HR as First and Only OTC Proton Pump Inhibitor in Original Prescription Formulation
8. SCAI Statement on A National Study of the Effect of Individual Proton Pump Inhibitors on Cardiovascular Outcomes in Patients Treated with Clopidogrel Following Coronary Stenting: The Clopidogrel Medco Outcomes Study
9. Alseres and BioAxone Amend License Agreement for Cethrin(R) and Rho Inhibitor Technology
10. Potential lung disease biomarkers yield clues to COX-2 inhibitor side effects
11. Experimental insulin-like growth factor receptor inhibitor reduced pancreatic cancer growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. 18, 2014 (HealthDay News) ... is starting to spread faster than ever, the World Health Organization ... viral infection were reported in just one week. That brings ... half of those reported in the past three weeks, the ... WHO has estimated that as many as 20,000 people could ...
(Date:9/18/2014)... Los Angeles, CA (PRWEB) September 18, 2014 ... manufacture and refine carbon dioxide, selling it to ... The largest markets for carbon dioxide are food and ... freeze products, such as fruits, vegetables or pizzas. The ... additive. Beverage manufacturers use the compound to carbonate soft ...
(Date:9/18/2014)... exercise is good for you. But new research from ... an added benefit for cancer patients undergoing chemotherapy. , ... found that combining exercise with chemotherapy shrunk tumors more ... professor in the School of Nursing and director of ... the senior author on the study, which appears in ...
(Date:9/18/2014)... WA (PRWEB) September 18, 2014 Qualis ... organizations, has published a white paper, “Advancing Primary ... of Health Information Technology.” , Authors Jeff Hummel, ... CCE provide guidance to organizations engaged in the work ... how health IT can bolster PCMH objectives, such as ...
(Date:9/18/2014)... one-day conference at the Milken Institute School of Public ... 2014 to discuss the Global Health Security Agenda (GHSA) ... this event is to invite discussion of proposed priorities ... action plans to curtail the current deadly Ebola outbreak. ... organizations and more than 50 countries have engaged in ...
Breaking Medicine News(10 mins):Health News:New Ebola Cases Top 700 in Just One Week, Officials Report 2Health News:New Ebola Cases Top 700 in Just One Week, Officials Report 3Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:Advancing Primary Care Through PCMH and HIT: New White Paper Connects the Dots 2Health News:Non-governmental stakeholders to discuss the Global Health Security Agenda 2
... Webinar: , , What: Coverity Webinar, ... 10 am PT, Where:, http://seminar2.techonline.com/registration/distrib.cgi?s=1346&d=2794 , ... the web at the, ... , Overview: , In this web seminar, ...
... Vista, LLC, a marketing,and information services firm focusing on ... Kevin Grossman, who has been with the company,for seven ... , In his new role, ... HRmarketer Services Group. Mr. Grossman will continue,to report ...
... DiseasePHOENIX, Feb. 12 Although major advances have been ... attention needs to be given to one of the ... -- the painful and often progressive condition called lymphedema, ... so much about cardiovascular disease, few physicians are familiar ...
... Md., Feb. 11 Dialysis Corporation of America (Nasdaq: ... fourth quarter and full year 2008 financial results on Thursday, ... company will also host a conference call in conjunction with ... following morning, Friday, March 6, 2009 at 10:00 AM EST. ...
... Study suggest streamlining of prescribing system to avoid ... -- Doctors often override electronic medication safety alerts ... prescribing drugs for patients, which suggests that physicians ... a U.S. study. , Researchers looked at ...
... Corporation (Nasdaq: RGEN ), a global leader ... today that the Company has received ISO 9001:2000 (ISO) ... and quality systems. ISO certification was granted for ... and related services underlying its Protein A business. ...
Cached Medicine News:Health News:Webinar Alert: Coverity Announces Verification and Validation of Medical Device Software with Static Analysis - A Review of FDA Guidance and Best Practices 2Health News:Kevin Grossman Named President of HRmarketer.com 2Health News:Vascular Experts Call for Increased Awareness of Growing Problem of Lymphedema 2Health News:Vascular Experts Call for Increased Awareness of Growing Problem of Lymphedema 3Health News:Dialysis Corporation of America Announces Fiscal Year 2008 Earnings Release Date 2Health News:Docs Override Most Electronic Drug Warnings 2Health News:Repligen Announces ISO 9001:2000 Certification 2Health News:Repligen Announces ISO 9001:2000 Certification 3
(Date:9/18/2014)... , Sept. 18, 2014  Decision Resources Group ... the United States , 54 percent ... BRAF inhibitor Tafinlar for BRAF -mutation-positive unresectable ... have prescribed GlaxoSmithKline,s MEK inhibitor Mekinist. Among current ... (42 percent and 43 percent, respectively) expects to ...
(Date:9/18/2014)... 18, 2014  KIYATEC announced today that it ... Innovation Research (SBIR) Phase II Contract from the ... institutes and centers that comprise the National Institutes ... two year award, KIYATEC will expand its 3D ... the forefront of cancer therapy strategies: 1) cancer,s ...
(Date:9/18/2014)... MEETING, Pa. , Sept. 18, 2014 ... trial solutions, was recognized as the Disruptive ... for its ePharmaONE cloud-based eClinical platform. This ... and electronic trial master file (eTMF), a ... solution, and ePharmaSolutions, ReferralPlus+ patient screening and ...
Breaking Medicine Technology:At One Year Post-Launch, Approximately One Half of Surveyed U.S. Medical Oncologists Have Prescribed Single-Agent Tafinlar and Mekinist to Their Malignant Melanoma Patients 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 3ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 2ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 3
... NORTHFIELD, Ill., Aug. 22, 2011 The latest developments ... be featured topics when more than 1,000 pathologists gather ... for the annual scientific meeting of the College ... THE Pathologists, Meeting™ will highlight advances in digital ...
... SANTA ANA, Calif., Aug. 22, 2011 Abbott (NYSE: ... expanded its Healon® family of ophthalmic viscosurgical devices (OVDs) ... The  clear, viscous, low molecular weight dispersive ... in cataract extraction, intraocular lens (IOL) implantation, corneal transplantation, ...
Cached Medicine Technology:Pathologists Gather to Focus on Advances in Molecular Testing, Digital Imaging, and Biospecimens 2Pathologists Gather to Focus on Advances in Molecular Testing, Digital Imaging, and Biospecimens 3Abbott Receives CE Mark for Healon EndoCoat Protective Gel for Cataract Surgery 2
... Flexible biopsy forceps are extremely delicate ... incompetent repair source, they can easily be ... turn, damage your endoscopes. , On the ... flexible biopsy forceps can have a virtually ...
Mobile offers full life cycle service for Sp02 accessories that are the vital link between pulse oximeter and patient...
... With our factory-quality repairs, physicians know ... why more hospitals turn to Mobile Instrument ... We offer a full line of carbide ... our four-way quality control process. You'll enjoy ...
Inquire...
Medicine Products: